Virtual Conference
Pharma Conference 2022

Mervat Dawood

Mansoura University, Egypt

Title: Umbilical cord blood platelet lysate as allogeneic eye drops for treatment of resistant corneal ulcer


Introduction: Persistent Corneal ulcer is considered chronic problem that bother patients and may result in complications that may lead to blindness. Recently, the use of platelet-rich plasma extracted from human umbilical cord blood has been tried to treat corneal ulcers, as it contains important growth factors and plasma proteins that play an important role in the healing process of persistent corneal ulcers due to the presence of high concentrations within the platelets of TGF, EGF, PDGF, and VEGF, higher two or three times than the blood plasma which promotes tissue regeneration.

Place of Research: Mansoura Ophthalmology Center and Mansoura Research Center for Cord Stem Cells (MARC-CSC) - Faculty of medicine - Mansoura University-Egypt

Materials and methods: Persistent corneal ulcer is defined as a corneal epithelium with or without stromal defect persisting for at least 2wks without improvement in size or depth despite conventional treatment. A prospective non randomized interventional study was carried out on 40 eyes aged from 6 to 65 years old with persistent corneal ulcer. Patients were classified according to cause persistent corneal ulcer into 4 groups: group I (14 eyes had dry eye), group II (6 eyes post keratoplasty), group III (4 eyes had corneal chemical burn), and group IV (16 eyes had other causes). CB-PRP was used from collection of 16 umbilical cord blood units (CB). CB platelet concentrate (CB-PC) was derived from lysis of platelets by repeated thawing &freezing. (CB-PC) in range of 600–1,100 × 106 platelets/ml in 8 (±5) mL and then stored at?80?C.). All patients underwent complete ophthalmic examination which involved best corrected visual acuity and slit-lamp Bio microscopy on each visit.

Results: There was a statistically significant improvement in the visual acuity post treatment in all studied groups (P value <0.001). Complete healing occurred in 71.4%, 66.7%, 50% and 62.5% patients in group I, II, III and IV respectively.

Conclusion: Platelet lysate of UCB is a novel therapeutic blood component with unique growth factors and anti–inflammatory compounds that can be used to treat resistant corneal ulcer.


To be added